Navigation Links
Study advances use of stem cells in personalized medicine
Date:11/26/2012

Johns Hopkins researchers report concrete steps in the use of human stem cells to test how diseased cells respond to drugs. Their success highlights a pathway toward faster, cheaper drug development for some genetic illnesses, as well as the ability to pre-test a therapy's safety and effectiveness on cultured clones of a patient's own cells.

The project, described in an article published November 25 on the website of the journal Nature Biotechnology, began several years ago, when Gabsang Lee, D.V.M., Ph.D., an assistant professor at the Johns Hopkins University School of Medicine's Institute for Cell Engineering, was a postdoctoral fellow at Sloan-Kettering Institute in New York. To see if induced pluripotent stem cells (iPSCs) could be used to make specialized disease cells for quick and easy drug testing, Lee and his colleagues extracted cells from the skin of a person with a rare genetic disease called Riley-Day syndrome, chosen because it affects only one type of nerve cell that is difficult if not impossible to extract directly from a traditional biopsy. These traits made Riley-Day an ideal candidate for alternative ways of generating cells for study.

In a so-called "proof of concept" experiment, the researchers biochemically reprogrammed the skin cells from the patient to form iPSCs, which can grow into any cell type in the body. The team then induced the iPSCs to grow into nerve cells. "Because we could study the nerve cells directly, we could for the first time see exactly what was going wrong in this disease," says Lee. Some symptoms of Riley-Day syndrome are insensitivity to pain, episodes of vomiting, poor coordination and seizures; only about half of affected patients reach age 30.

In the recent research at Johns Hopkins and Memorial Sloan-Kettering, Lee and his co-workers used these same lab-grown Riley-Day nerve cells to screen about 7,000 drugs for their effects on the diseased cells. With the aid of a robot programmed to analyze the effects, the researchers quickly identified eight compounds for further testing, of which one SKF-86466 ultimately showed promise for stopping or reversing the disease process at the cellular level.

Lee says a clinical trial with SKF-86466 might not be feasible because of the small number of Riley-Day patients worldwide, but suggests that a closely related version of the compound, one that has already been approved by the U.S. Food and Drug Administration for another use, could be employed for the patients after a few tests.

The implications of the experiment reach beyond Riley-Day syndrome, however. "There are many rare, 'orphan' genetic diseases that will never be addressed through the costly current model of drug development," Lee explains. "We've shown that there may be another way forward to treat these illnesses."

Another application of the new stem cell process could be treatments tailored not only to an illness, but also to an individual patient, Lee says. That is, iPSCs could be made for a patient, then used to create a laboratory culture of, for example, pancreatic cells, in the case of a patient with type 1 diabetes. The efficacy and safety of various drugs could then be tested on the cultured cells, and doctors could use the results to help determine the best treatment. "This approach could move much of the trial-and-error process of beginning a new treatment from the patient to the petri dish, and help people to get better faster," says Lee.


'/>"/>

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine
Source:Eurekalert

Related biology news :

1. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
2. Algae Biomass Organization hails new UCSD study showing saltwater algae viable for biofuels
3. Study reveals the proteins expressed by human cytomegalovirus
4. New public gut bacteria study expected to reach around world
5. Researchers study links between conflict and fisheries in East Africa
6. NJIT civil engineer receives NSF grant to study storms impact on Jersey Shore
7. New whale shark study used metabolomics to help understand shark and ray health
8. NIST study suggests carbon nanotubes may protect DNA from oxidation
9. New study finds milk-drinking kids reap physical benefits later in life
10. New brain gene gives us edge over apes, study suggests
11. Study investigates headshaking in horses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 24, 2017 , ... Nanomedical Diagnostics ... for fragment-based screening, will showcase its proprietary Field Effect Biosensing (FEB) ... Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8. , ...
(Date:1/24/2017)... ... January 23, 2017 , ... Edward ... first-ever recipient of the National Academy of Sciences Prize in Food and Agriculture ... nutrition. , The annual National Academy of Sciences (NAS) Prize in Food and ...
(Date:1/24/2017)... , Jan. 23, 2017  Today, the Fisher Center ... have funded an important study that could lead to ... onset of Alzheimer,s disease. This groundbreaking research was conducted ... led by Nobel Laureate Dr. Paul Greengard , ... disease. Fisher Center scientists have linked a ...
(Date:1/23/2017)... - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) ... Zealand based Phase 1 trial with severe ... in reducing inflamed protein biomarkers in patients with severe ... that this is the first time in medical history ... made between epigenetic regulation and its potential for positive ...
Breaking Biology Technology: